Michel Klein

Title: Michel Klein: Innovator in Tuberculosis Vaccine Development

Introduction

Michel Klein is a notable inventor based in Zaandijk, Netherlands. He has made significant contributions to the field of medicine, particularly in the development of vaccines aimed at combating latent tuberculosis infections. His innovative approach has the potential to change the landscape of tuberculosis treatment and prevention.

Latest Patents

Michel Klein holds a patent for a vaccine designed to treat or prevent the establishment of latent tuberculosis infections. This vaccine comprises a recombinant that overexpresses the transcription factor DosR. The overexpression is sufficient to induce the production of dosR regulon genes or proteins. When administered, the vaccine prompts the host to mount an immune response to the dosR regulon proteins, thereby protecting against the establishment, persistence, or reactivation of latent tuberculosis. He has 1 patent to his name.

Career Highlights

Throughout his career, Michel Klein has worked with prominent organizations in the field of vaccine research. Notably, he has been associated with the Aeras Global Tuberculosis Vaccine Foundation and Leland Stanford Junior University. His work in these institutions has allowed him to contribute to groundbreaking research and development in tuberculosis vaccines.

Collaborations

Michel Klein has collaborated with esteemed colleagues in his field, including Mario Alberto Flores-Valdez and Gary K. Schoolnik. These collaborations have further enriched his research and have played a crucial role in advancing the understanding of tuberculosis and vaccine development.

Conclusion

Michel Klein's innovative work in developing a vaccine for latent tuberculosis infections highlights his commitment to improving public health. His contributions are vital in the ongoing battle against tuberculosis, and his patent reflects the potential for significant advancements in vaccine technology.